The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release drugs and drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals.
NIH/NIAID: 1F31AI129549-01A1; Amer Al-Khouja; 05/01/17 - 04/30/19
NIH/NIAID: 5R01AI120748-02; Marc Michael Baum (PI); 06/26/15 - 05/31/20
NIH/NIAID: 1R01AI131416-01; Andrew Martin Bellinger (PI); 03/22/17 - 02/28/22
NIH/NIAID: 4R01AI073146-09; Victor J. Garcia-Martinez (PI); 01/05/02 - 07/31/17
NIH/NIAID: 5R01AI117740-03; Christopher J. Destache (PI); 02/04/16 - 01/31/18
Non-adherence to anti-retroviral therapy by HIV+ patients results in increased viral loads and risk of emergence of drug-resistant HIV strains. This poses a major public health threat. Lyndra Co. has developed an orally available, long-acting drug delivery system that it will now formulate to deliver anti-retrovirals.
In this application, researchers propose to utilize novel synthetic chemistry to develop a series of aliphatic tenofovir prodrugs designed to greatly enhance cellular uptake and to provide prolonged intracellular exposure to molecules with potent antiviral activity. They will further extend systemic exposure to these compounds by delivering them in slow-release nanoparticle formulations. They believe that with this “dual-modulation” of drug presentation we will provide systemic exposure to therapeutic concentrations of highly active antiviral compounds for periods of at least four weeks following intramuscular injection.
NIH/NIAID 5R01AI120748-02; Marc M. Baum (PI); 06/26/15 - 05/31/20
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from single institutions, or consortia of institutions, to identify existing anti-HIV molecules...